Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial

By sjmartinez • October 15, 2024

Chew KW, McGinley B, Moser C, Li JZ, Evering TH, Ritz J, Javan AC, Margolis D, Wohl DA, Hughes MD, Daar ES, Currier JS, Eron JJ, Smith DM; ACTIV-2/A5401 Study Team. Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial. J Infect Dis. 2024 Oct 14:jiae501. doi: 10.1093/infdis/jiae501. Epub ahead of print. PMID: 39400063.

Tags: covid-19, COVID-19 treatment, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, non-hospitalized adults, Publications, SARS-CoV-2, symptom rebound, viral rebound

Less is More: A Cost and Environmental Waste Analysis in Nonadherence to Antibiotic Prophylaxis Guidelines in Clean Ambulatory Surgical Procedures

Sandigo-Saballos I, Montero S, Lee P, Lee H, Chen KT. Less is More: A Cost and Environmental Waste Analysis in Nonadherence to Antibiotic Prophylaxis Guidelines[...]

Topological Data Analysis in the Assessment of Coronary Atherosclerosis: A Comprehensive Narrative Review

Singh Y, Hathaway QA, Farrelly C, Budoff MJ, Erickson B, Collins JD, Blaha MJ, Leiner T, Lopez-Jimenez F, Rozenblit J, Sarkar D, Carlsson G. Topological[...]

Coronary Artery Bypass Grafting Is Rarely Done in the Acute Care of ST-elevation Myocardial Infarction Patients Treated by Emergency Medical Services

Toy J, Lauer C, Kaji AH, Thomas JL, Megowan N, Bosson N, Gausche-Hill M, Dhawan P, Kloner RA, Rasnake S, French W, Schlesinger S. Coronary[...]